Form 4: Clover Health Director Granted 79,365 RSUs

Clover Health Investments Corp. Director Carladenise Armbrister Edwards was granted 79,365 restricted stock units, vesting in one year.

Summary

• Carladenise Armbrister Edwards, a Director of Clover Health Investments, Corp. (CLOV), was granted 79,365 shares of Class A Common Stock.
• These shares represent time-based Restricted Stock Units (RSUs).
• The RSUs will vest in full on January 6, 2027, subject to continued service as a director through such vesting date.
• The transaction date for this grant was January 6, 2026.
• Following this transaction, the reporting person beneficially owns 352,592 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation event for a director, which generally indicates stability and continued alignment of interests between the director and the company's future performance.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value.
• The director's beneficial ownership increased by 79,365 shares, demonstrating continued commitment to the company.

Negatives

• No direct negatives are identified in this compensation-related filing.

Risks

• Vesting of the 79,365 Restricted Stock Units is contingent on the director's continued service through January 6, 2027.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in full on January 6, 2027, contingent upon the director's continued service to the company through that date.

Industry Context

This transaction represents a standard equity compensation practice for directors in publicly traded companies, particularly within the healthcare technology sector. Such grants are designed to align the interests of board members with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units (RSUs), are a common component of director compensation across various industries, including healthcare technology.
• The one-year cliff vesting schedule for these RSUs is a typical structure used to incentivize director retention and align their focus with short-to-medium term strategic objectives.
• The size of the grant should be evaluated against compensation practices for directors at peer companies within the healthcare technology sector, considering factors such as company market capitalization and the director's specific responsibilities, though this filing does not provide such comparative data.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially fostering more shareholder-centric decision-making.
• Employees: No direct impact on employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• The 79,365 Restricted Stock Units are expected to vest on January 6, 2027, provided the director continues their service.

Key Dates

Keywords

Clover Health, CLOV, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant